While we know that statin treatment reduces the risk of stroke, heart attack and heart deaths in people at moderate-to-high risk, or with high cholesterol, in REPRIEVE statins decreased the risk in those at low-to-moderate risk, and with 'normal' cholesterol levels who would not usually be considered candidates for treatment.

In this interview, Pamela S. Douglas, MD, MACC, and Roger S. Blumenthal MD, FACC, discuss Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Dhanunjaya "DJ" Lakkireddy, MBBS, FACC, and Alison L. Bailey, MD, FACC discuss the top takeaways from 2023 in cardiac electrophysiology including AF and the latest guidelines and ARTESIA and MONITOR-AF studies.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Noel Bairey Merz, MD, FACC, and Alison L. Bailey, MD, FACC discuss the top takeaways from 2023 in Preventive Cardiology including the CLEAR-Outcomes, REPRIEVE, and SELECT trials.  

  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  

In this interview, Clyde Yancy MD, MSc, FACC, and Alison L. Bailey MD, FACC, discuss the Top Takeaways from 2023 in Heart Failure. Dr. Yancy discusses trials including STEP-HFpEF, SELCT and DELIVER. 

  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Christopher M. Kramer MD, FACC, and Alison L. Bailey MD FACC, discuss the Top Takeaways from 2023 in CV Imaging. Dr. Kramer discusses the PRECISE trial, AI evolution in imaging and more. 

  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Deepak Bhatt, MD, FACC, and Alison L. Bailey, MD FACC, discuss Top Takeaways from 2023 in Interventional Cardiology. Dr. Bhatt discusses trials including FIRE, MULTISTARS, and TRILUMINATE.  

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

ORBITA-2 was designed to test whether stents reduce angina more than a placebo procedure in patients with single or multivessel disease on little or no antianginal medication at 12 weeks of follow up.

In this interview, Christopher Rajkumar, MD, Rasha Al-Lamee, MD, and William E. Boden MD, FACC, discuss AHA Late-Breaker: Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomized, Placebo-Controlled Trial.

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Nonischemic cardiomyopathy (NICM) is common and patients are at significant risk for early mortality secondary to ventricular arrhythmias. 

 In this interview, Jonathan Chrispin MD, FACC, and Dhanunjaya “DJ” Lakkireddy MBBS, FACC, discuss Risk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy. 

  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Detecting HF (cardiac dysfunction) during pregnancy and shortly after having a baby can be challenging for health care professionals and is often delayed. The use of a device powered by artificial intelligence can assist health care providers in identifying this condition earlier. 

 In this interview, Demilade A. Adedinsewo MD, FACC, and Steven E. Nissen MD, MACC, discuss the AHA Late-Breaker: Screening for Peripartum Cardiomyopathies Using an Artificial Intelligence Enhanced Digital Stethoscope: A Randomized Clinical Trial. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL